Amgen Inc. (AMGN)
|Net Income (ttm)||6.58B|
|Ex-Dividend Date||Aug 17, 2022|
|Day's Range||225.17 - 230.00|
|52-Week Range||198.64 - 258.45|
|Price Target||258.18 (+14.5%)|
|Earnings Date||Oct 31, 2022|
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment o... [Read more...]
In 2021, Amgen's revenue was $25.98 billion, an increase of 2.18% compared to the previous year's $25.42 billion. Earnings were $5.89 billion, a decrease of -18.87%.Financial Statements
According to 36 analysts, the average rating for AMGN stock is "Buy." The 12-month stock price forecast is 258.18, which is an increase of 14.54% from the latest price.
These drugmakers seem to have a knack for innovation.
Both the S&P 500 and the tech-heavy Nasdaq Index are in bear market while the Dow Jones in the only of the three main indexes not to have bear market status.
Amgen Inc. ( AMGN , Financial) CEO Robert Bradway contends that small and mid-sized biotechs may find it much harder to remain independent, a situation that Fierce Pharma reported was exacerbated by new...
Makers of the top selling drugs in the United States are costing patients billions of dollars and worsening a drug pricing crisis by abusing the U.S. patent system to stifle competition and inflate pric...
Amgen Inc.'s AMGN, +0.17% Lumakras, which already has a type of conditional approval to treat lung cancer, produced mixed results in a closely watched clinical trial comparing the drug to docetaxel, a c...
Amgen CEO on New Products, M&A, Drug Pricing Legislation
Amgen Inc. Chairman and Chief Executive Officer Robert Bradway discusses the biopharmaceutical company's new products, merger and acquisition strategy, and the impact of US drug pricing legislation on "...
These are stocks all income investors should consider buying and holding.
Here's who could benefit from Biden's biotech initiative, according to Oppenheimer's Jared Holz
Oppenheimer's Jared Holz on President Biden's cancer initiative and what it means for biotech in the U.S. With CNBC's Melissa Lee and the Fast Money traders, Tim Seymour, Courtney Garcia, Guy Adami and ...
THOUSAND OAKS, Calif. , Sept. 12, 2022 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at Bank of America Merrill Lynch's 2022 Global Healthcare Conference at 4:55 a.m.
Amgen, Inc. (NASDAQ: AMGN) shares are trading lower by 4.11% to $237.51 during Monday's pre-market session following FDA approval of Bristol Myers Squibb Co's (NYSE: BMY) plaque psoriasis drug Sotyktu, ...
LUMAKRAS® (SOTORASIB) COMBINED WITH VECTIBIX® (PANITUMUMAB) SHOWS CONFIRMED 30% OBJECTIVE RESPONSE RATE IN PATIENTS W...
Phase 1b Results Demonstrate Encouraging Median Progression-Free Survival of 5.7 Months in Difficult-to-Treat Patient Population THOUSAND OAKS, Calif. , Sept. 12, 2022 /PRNewswire/ -- Amgen (NASDAQ: AMG...
Amgen Inc's Lumakras pill reduced the risk of disease progression in patients with advanced lung cancer by 34% compared with chemotherapy in a clinical trial, the company said on Sunday.
LUMAKRAS®/LUMYKRAS® (SOTORASIB) DEMONSTRATES SUPERIOR PROGRESSION-FREE SURVIVAL OVER DOCETAXEL IN FIRST POSITIVE PHAS...
At 1-Year, Progression-Free Survival was 25% for LUMAKRAS Versus 10% for Docetaxel LUMAKRAS Met Key Secondary Endpoint of Objective Response Rate THOUSAND OAKS, Calif. , Sept. 11, 2022 /PRNewswire/ -- A...
Amgen's biosimilar drug is close to stealing away sales from AstraZeneca's rare disease drug called Soliris.
THOUSAND OAKS, Calif. , Sept. 8, 2022 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at Morgan Stanley's 2022 Global Healthcare Conference at 9:10 a.m.
SPROUT Data Show Otezla Resulted in Significant Improvements in Measures of Moderate to Severe Plaque Psoriasis at Week 16 Compared With Placebo in Children Ages 6-171 DISCREET 16-week Data Demonstrated...
THOUSAND OAKS, Calif. , Sept. 7, 2022 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will host a webcast call for the investment community in conjunction with the European Society for Medical Oncology Annual Congr...
Amgen stock (NASDAQ: AMGN) has seen an 8% rise this year, far better than the broader S&P500 index, which is down 18%.
THOUSAND OAKS, Calif. , Sept. 2, 2022 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at Wells Fargo's 2022 Global Healthcare Conference at 9:45 a.m.
THOUSAND OAKS, Calif. , Sept. 2, 2022 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at Citi's 2022 Global Healthcare Conference at 8:50 a.m.
The top five biotech stocks today have several commonalities: strong ratings. Some also show promising charts and are Tech Leaders.
Amgen's (AMGN) phase III CodeBreaK 200 study evaluating once-daily oral, Lumakras, for treating KRAS G12C-mutated non-small cell lung cancer meets its primary endpoint.